GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » TDS Pharm Co Ltd (XKRX:464280) » Definitions » Net Income Including Noncontrolling Interests

TDS Pharm Co (XKRX:464280) Net Income Including Noncontrolling Interests : ₩1,809 Mil (TTM As of Mar. 2025)


View and export this data going back to 2024. Start your Free Trial

What is TDS Pharm Co Net Income Including Noncontrolling Interests?

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

TDS Pharm Co's Net Income Including Noncontrolling Interests for the three months ended in Mar. 2025 was ₩366 Mil. Its Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Mar. 2025 was ₩1,809 Mil.

TDS Pharm Co Net Income Including Noncontrolling Interests Historical Data

The historical data trend for TDS Pharm Co's Net Income Including Noncontrolling Interests can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TDS Pharm Co Net Income Including Noncontrolling Interests Chart

TDS Pharm Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Net Income Including Noncontrolling Interests
1,351.29 2,062.85 3,455.61 4,687.96 3,717.81

TDS Pharm Co Quarterly Data
Dec20 Dec21 Dec22 Mar23 Sep23 Dec23 Mar24 Sep24 Dec24 Mar25
Net Income Including Noncontrolling Interests Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,541.08 808.96 846.69 595.77 366.36

TDS Pharm Co Net Income Including Noncontrolling Interests Calculation

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩1,809 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TDS Pharm Co Net Income Including Noncontrolling Interests Related Terms

Thank you for viewing the detailed overview of TDS Pharm Co's Net Income Including Noncontrolling Interests provided by GuruFocus.com. Please click on the following links to see related term pages.

TDS Pharm Co Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » TDS Pharm Co Ltd (XKRX:464280) » Definitions » Net Income Including Noncontrolling Interests
Comparable Companies
XKRX:118000 XKRX:014570 XKRX:004720 XKRX:200780 XKRX:307750 LLY JNJ ABBV OCSE:NOVO B XSWX:ROG XSWX:NOVN LSE:AZN MRK AMGN GILD PFE XPAR:SAN BMY TSE:4519 LSE:GSK
Traded in Other Exchanges
N/A
Address
253 Pangyo-ro, Pangyo Inno Valley, Building C, Room 403, Bundang-gu, Gyeonggi-do, Seongnam-si, KOR, 13486
Website
https://www.tdspharm.com
TDS Pharm Co Ltd is engaged in the development and manufacturing of the Transdermal Drug Delivery System (TDDS), which is growing as a high-growth business sector in the field of drug delivery systems (DDS). The Transdermal Drug Delivery System (TDDS) is a drug delivery system that delivers drugs through the skin at a controlled speed. It has the advantages of increasing patient compliance with drugs, maximizing efficacy and effectiveness, such as minimizing side effects in the liver and digestive organs, controlling absorption rate, controlling discontinuation, controlling effective blood concentration, and enabling long-term continuous administration, and reducing burden compared to oral and injection drugs.

TDS Pharm Co Headlines

No Headlines